Analyst Price Target is $1.60
▲ +223.23% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Myomo in the last 3 months. The average price target is $1.60, with a high forecast of $1.60 and a low forecast of $1.60. The average price target represents a 223.23% upside from the last price of $0.50.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Myomo. This Buy consensus rating has held steady for over two years.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.